Announcements Trials
Browse Landscape

Phase

Phase 1/2 7Phase 2 2Phase 1 1

Status

Completed 7Recruiting 3Terminated 2Not yet recruiting 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 87Carcinoma, Non-Small-Cell Lung 76Breast Neoplasms 73Recurrence 65Colorectal Neoplasms 63Pancreatic Neoplasms 60Melanoma 58Advanced Solid Tumor 57Multiple Myeloma 56Carcinoma, Hepatocellular 56Lymphoma 53Leukemia, Myeloid, Acute 53Advanced Solid Tumors 53Neoplasm Metastasis 51Stomach Neoplasms 47Precursor Cell Lymphoblastic Leukemia-Lymphoma 44Lymphoma, B-Cell 40Solid Tumor 39Lymphoma, Non-Hodgkin 39Ovarian Neoplasms 38Lung Neoplasms 36Glioblastoma 35Prostatic Neoplasms 34Leukemia 28Head and Neck Neoplasms 27Leukemia, Lymphocytic, Chronic, B-Cell 26Uterine Cervical Neoplasms 25Burkitt Lymphoma 24Esophageal Neoplasms 23Urinary Bladder Neoplasms 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Unknown × Diabetes Mellitus, Insulin-Dependent, 12 × Clear all
NCT05235438 2023-05-24

Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 1 Unknown
16 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡